Skip to content
healthcare.dev
Get a free key

SHISEIDO FUTURE Solution LX INFINITE TREATMENT PRIMER

NDC 58411-657, TITANIUM DIOXIDE, OCTINOXATE, and ENSULIZOLE, emulsion, from SHISEIDO AMERICAS CORPORATION.

Product NDC
58411-657
Status
Listed
Labeler
SHISEIDO AMERICAS CORPORATION
Dosage form
EMULSION
Route
TOPICAL
Product type
HUMAN OTC DRUG
Marketing category
OTC MONOGRAPH DRUG
Application
M020
DEA schedule
None
Request
curl https://api.healthcare.dev/v1/drugs/ndc/58411-657 \
  -H "Authorization: Bearer $HDEV_API_KEY"

Product

Active ingredients and packages

Active ingredients

  • TITANIUM DIOXIDE1.77 g/40mL
  • OCTINOXATE1.71 g/40mL
  • ENSULIZOLE.428 g/40mL
Package NDCNDC-11Package
58411-657-10584110657101 TUBE in 1 CARTON (58411-657-10) / 40 mL in 1 TUBE

Linked data

RxNorm, label and prices

RxNorm concepts

RxNorm links no concept to this product's packages.

Related lookups

No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.

Use it

Look up 58411-657 from code or an agent

curl
curl https://api.healthcare.dev/v1/drugs/ndc/58411-657 \
  -H "Authorization: Bearer $HDEV_API_KEY"
MCP prompt
Using the healthcare.dev MCP server, look up NDC 58411-657. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Get a free keyNDC docsConnect the MCP server

Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.